Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Límite
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Transl Med ; 19(1): 128, 2021 03 29.
Artículo en Inglés | MEDLINE | ID: mdl-33781275

RESUMEN

BACKGROUND: Omega-3 polyunsaturated fatty acids (n3-PUFAs) may exert beneficial effects on the immune system of patients with viral infections. This paper aimed to examine the effect of n3-PUFA supplementation on inflammatory and biochemical markers in critically ill patients with COVID-19. METHODS: A double-blind, randomized clinical trial study was conducted on 128 critically ill patients infected with COVID-19 who were randomly assigned to the intervention (fortified formula with n3-PUFA) (n = 42) and control (n = 86) groups. Data on 1 month survival rate, blood glucose, sodium (Na), potassium (K), blood urea nitrogen (BUN), creatinine (Cr), albumin, hematocrit (HCT), calcium (Ca), phosphorus (P), mean arterial pressure (MAP), O2 saturation (O2sat), arterial pH, partial pressure of oxygen (PO2), partial pressure of carbon dioxide (PCO2), bicarbonate (HCO3), base excess (Be), white blood cells (WBCs), Glasgow Coma Scale (GCS), hemoglobin (Hb), platelet (Plt), and the partial thromboplastin time (PTT) were collected at baseline and after 14 days of the intervention. RESULTS: The intervention group had significantly higher 1-month survival rate and higher levels of arterial pH, HCO3, and Be and lower levels of BUN, Cr, and K compared with the control group after intervention (all P < 0.05). There were no significant differences between blood glucose, Na, HCT, Ca, P, MAP, O2sat, PO2, PCO2, WBCs, GCS, Hb, Plt, PTT, and albumin between two groups. CONCLUSION: Omega-3 supplementation improved the levels of several parameters of respiratory and renal function in critically ill patients with COVID-19. Further clinical studies are warranted. Trial registry Name of the registry: This study was registered in the Iranian Registry of Clinical Trials (IRCT); Trial registration number: IRCT20151226025699N3; Date of registration: 2020.5.20; URL of trial registry record: https://en.irct.ir/trial/48213.


Asunto(s)
COVID-19/dietoterapia , COVID-19/diagnóstico , Enfermedad Crítica/terapia , Ácidos Grasos Omega-3/farmacología , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/análisis , Biomarcadores/sangre , Análisis de los Gases de la Sangre , Glucemia/efectos de los fármacos , Glucemia/metabolismo , COVID-19/mortalidad , COVID-19/fisiopatología , Enfermedad Crítica/mortalidad , Suplementos Dietéticos , Método Doble Ciego , Ácidos Grasos Omega-3/administración & dosificación , Femenino , Hematócrito , Humanos , Mediadores de Inflamación/análisis , Mediadores de Inflamación/sangre , Irán/epidemiología , Riñón/efectos de los fármacos , Riñón/fisiopatología , Riñón/virología , Masculino , Persona de Mediana Edad , Mortalidad , Pronóstico , Sistema Respiratorio/efectos de los fármacos , Sistema Respiratorio/fisiopatología , Sistema Respiratorio/virología , SARS-CoV-2/efectos de los fármacos , Análisis de Supervivencia , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA